Atossa Therapeutics Completes Enrollment Of 80mg Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen For ER+ / HER2- Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics has completed enrollment for the 80mg pharmacokinetic run-in cohort in its Phase 2 EVANGELINE clinical trial. The trial is evaluating (Z)-Endoxifen for ER+ / HER2- breast cancer.
July 22, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics has completed enrollment for the 80mg pharmacokinetic run-in cohort in its Phase 2 EVANGELINE clinical trial, which is evaluating (Z)-Endoxifen for ER+ / HER2- breast cancer.
The completion of enrollment in a clinical trial phase is a significant milestone for biotech companies. It indicates progress in the development of their drug candidate, which can positively impact investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100